The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi everyone. Hope you are all well,
Just reading back some of the comments. Not been on the board a while. Still invested. Fingers crossed for the future. Check back in a few months. Biotech has got battered in the last 12 months. Lets hope for a better 2022,
https://www.ft.com/content/c90d17c6-6196-4c8a-88c2-e2cef9a692f2
P.S blocked ‘Sangi’. Seems bitter about something. Not sure what. So atleast the time spent reading back on the board was worthwhile. And im not related to the new person hired by tils lol. So inside info unfortunately :( gLa
$60 trade today, on Accustem and down over 13% Beggars belief.
Seabass
A good anology perhaps we should rename the sinker to TiziTanic !
Eventually got them valued today and are live.....just about a live, **** value but at least I have them....deep in the red !!Accustom still zero value.
Thank you, appreciate the reply. Yes my Accustem are still showing as zero too. All in all, a shocking way to treat UK investors. Learning every day!
I assume the Regulator in the UK is the FCA and in the US the SEC. You could always email TLSA to say you will be making a formal complaint to both the FCA and the SEC. You will probably hear nothing from TLSA so should be prepared to make a formal complaint.
BigRed. As soon as TILS announced they were only going to trade on NASDAQ I put in motion a transfer of account from Barclays to AJ Bell because I knew Barclays will not let you trade international shares. In the past Barclays have screwed me by selling a share in the market the day before delisting. I was not given the opportunity of having a share certificate. You at least will eventually receive a share certificate, you then will have to find a broker who will sell your certificated shares on your behalf via NASDAQ. I am aware that Barclays may be moving to international dealing, however I am now with AJB and my TLSA shares are held in my ISA and are tradeable.
We await further news about our dividend Accustem (ACCM) shares which have not yet been listed on NASDAQ.
Further, interim data from a clinical study in a patient with secondary progressive multiple sclerosis (SPMS) also indicated that the treatment was not only well-tolerated, but it also produced clinical response after three months of treatment. Consequently, the Food and Drug Administration (FDA) reviewed the safety data and allowed continuation of dosing. Six-month treatment results in this patient will be reported in the first quarter of 2022.
SJ1
4D has SO selling down itr of 10% of the stock if he clears totally. Tils are now buying back stock - itr of 6% at these prices. So that could effect it further.
BB
PS. I'm buying 4d as they are both 70% down over 12 months
Hi all, first time poster but increasingly frustrated so wanted to reach out to ask if anyone else is having similar issues.
Relatively new to investing and didn’t check my holdings regularly so when TILS decided to switch to US I’ve been left unable to cut my losses and run. Latest email from Barclays is cut below, it’s been going on for months now.
‘Unfortunately, we are still not yet in a position to provide you with our final response.
Our continued efforts at communication with the issuing party continue to receive the same response, that the physical certificate has been issued and could take several weeks, but has still not been received as yet.
Please be aware that we have over 300 clients affected by this issue and I can assure you that senior management are aware and this is being dealt with as a priority issue.
I will update you again no later than 24 February’
Any advice welcomed, may be a daft question but can we do anything by way of complaining that we’ve been unable to sell these since the news?
Cheers
Sang, as you know, the distressed seller coupled with market sentiment is pulling the price down over at 4D.
There is obviously a decent value attributed to anti CD3 mabs, just look at the valuation of PRVB which seems a lofty valuation. It has also recovered well this week along with other Nasdaq bio stocks.
If it does happen and TLSA eventually get some of these proposed Phase 2 trials out of the starting blocks I’m sure we will see the SP move through the gears nicely.
Add in some positive Accustem news and this could suddenly look like a decent investment.
That this company with no prospects as no trials is valued at twice that of 4D, a company running multiple trials with readouts due and partnerships with Merck and Pfizer
I mean it's mind blowing
I watch my investment continue to fall with no way of dealing. A sinking ship without lifeboats.
I agree bonidel its the don't give a f**k attitude them pair of c**ts have for us pi,s I could not wish them enough bad luck I don't care if they are doing a multi million or billion pound or dollar deal they could at lest put a RNs saying they have NDA,s in place but the more I think about it they probably cant because they have f**k*d every thing up , how can you fail to sell a product that is 50% better than anybody else's , they are absolutely pathetic or a pair of con men
Volume is rubbish. News is badly needed to raise the interest levels of investors here. A new wave of investors is needed. It seems existing investors are either maxed out or fed up so probably barely topping up now.
Hopefully we reach that quickly so Long sufferers.. I mean long term holders… can average down and dump this at the next BS spike up to this range or whatever.
I wouldn’t worry about it. Collectively shareholders have lost hundreds of millions & the bod can’t even be bothered to comment. Uk shareholders unable to trade on some accounts still.
Biotech sector has been hammered so that’s not the bod fault but the mishandling of Accustem, poor comms, missed trials & treating shareholders with contempt most certainly is!
Just avoid the issue, That seems to be GC & KS tactic which is probably why the renalytix main guy was sticking the knife in at the dechert conference. He kind of implied that tils hasn’t been honest with shareholders when disagreeing totally with GC about issues with aim. Said aim did really well for him as he was always as transparent as he could be with shareholders.
GC had a face like a tils PI when he said this.
Had to fill a form out on IG last night - have the privilege of paying 15% tax to US when I sell. Thanks TILS
Any comments?
Were they not supposed to be added to US?
I win!!
That's not a trial you absolute tool. It's compassionate use.
It will produce an anecdote.
Amazing how all the other pharma companies are doing it wrong running testing in hundreds and thousands of patients.
The first patient started dosing 24th May 2021.
So by my reckoning they have been dosed for over 8 months now!!!
They must have excellent data for the second to start dosing, so methinks we are a bit further along the road than we think!
Hardly a bunch of scammers!
On the contrary, if this is what they are up to, buying back shares, not rocket science , but should enhance shareholder value to boot
https://www.nasdaq.com/market-activity/stocks/dffn/advanced-charting?timeframe=5y